<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: We performed a systematic review and meta-analysis to investigate the prognostic value of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in blood (circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells [CTCs]) or bone marrow (BM) (disseminated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells) of patients with resectable colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> or widespread <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: The following databases were searched in May 2011: MEDLINE, EMBASE, Science Citation Index, BIOSIS, Cochrane Library </plain></SENT>
<SENT sid="2" pm="."><plain>Studies that investigated the association between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in blood or BM and long-term outcome in patients with metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were included </plain></SENT>
<SENT sid="3" pm="."><plain>We extracted hazard ratios (HRs) and confidence intervals (CIs) from the included studies and performed random-effects meta-analyses for survival outcomes </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The literature search yielded 16 studies representing 1,491 patients </plain></SENT>
<SENT sid="5" pm="."><plain>The results of 12 studies representing 1,329 patients were suitable for pooled analysis </plain></SENT>
<SENT sid="6" pm="."><plain>The overall survival (HR, 2.47; 95 % CI 1.74-3.51) and progression-free survival (PFS) (HR, 2.07; 95 % CI 1.44-2.98) were worse in patients with CTCs </plain></SENT>
<SENT sid="7" pm="."><plain>The subgroup of studies with more than 35 % CTC-positive patients was the only subgroup with a statistically significant worse PFS </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> eight studies that performed multivariable analysis identified the detection of CTCs as an independent prognostic factor for survival </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The detection of CTCs in peripheral blood of patients with resectable colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> or widespread metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is associated with disease progression and poor survival </plain></SENT>
</text></document>